Recently two novel cancer-related glycoproteins, thrombospondin 1 (THBS1) and cathepsin D (CTSD) were proposed as blood-based biomarkers that outperformed PSA in distinguishing benign disease from prostate cancer in men with enlarged prostate gland [42]. Here, CTSD is linked to prostate cancer.